In 2013, GSK and Save the Children formed an ambitious and strategic global partnership combining their expertise, resources and influence to help save the lives of one million children.
Our multi-layered, shared value partnership incorporates programme work, advocacy and campaigning, employee engagement, marketing initiatives and the research and development of child friendly medicines.
Together we are focused on widening vaccine coverage to children in the hardest to reach communities, increasing investment in training frontline health workers, and researching new affordable nutritional products to help alleviate child malnutrition.
Launching flagship programmes to help save children’s lives
We have set up flagship programmes in the Democratic Republic of Congo and Kenya to tackle child mortality and are working to establish models that can be adopted, expanded and replicated in other developing countries
Since 2011 Save the Children has been a partner of GSK’s initiative to reinvest 20% of the profits it makes in the world’s least developed countries back into projects which strengthen healthcare infrastructure.
Together we have helped fund the training of more than 5,000 health workers across West and Central Africa, Sudan, Haiti and Yemen.
Developing child-friendly medicines to reduce child mortality and new-born deaths
Through our partnership, GSK and Save the Children are working together to accelerate the availability of life-saving medicines designed especially for children.
This includes the antiseptic chlorhexidine – commonly used in mouthwash – which will be reformulated into a gel for cleansing the umbilical cord stump of newborn babies to prevent serious infection, a major cause of newborn death in poor countries.
Uniting a global workforce
Employees around the world are encouraged to take an active role in the partnership through both fundraising and the sharing of skills and expertise. By August 2014 GSK employees had raised an incredible £940,000.
Save the Children also benefits from PULSE, GSK’s skills based volunteering programme. In 2014, 18 employees are undertaking secondments with Save the Children offices globally, including in Peru, the Philippines, Kenya and the UK.
Supporting life-saving innovation in the developing world
In June 2014, the second GSK and Save the Children $1 million Healthcare Innovation Award fund was launched.
The purpose of the Award is to identify and reward innovations in healthcare that have proven to be successful in reducing child deaths in developing countries. In 2013, we received nearly 100 applications from 29 countries.
The highest award went to Friends of Sick Children in Malawi for their innovative low-cost adaptation of a breathing device to help newborn babies in respiratory distress.
Sir Andrew Witty, CEO of GSK said:
“A partnership of this scale gives us an opportunity to do something amazing – to save the lives of one million children, and to transform the lives of millions more. At GSK we are motivated by developing innovative life-saving medicines and getting them to the people that need them.
“By joining forces with Save the Children, we can amplify these efforts to create a new momentum for change and stop children dying from preventable diseases. I hope this partnership inspires GSK employees and sets a new standard for how companies and NGOs can work together towards a shared goal.”